Imara’s (NASDAQ:IMRA) IMR-687 received European Commission orphan drug designation for the treatment of sickle cell disease.
In a statement, Imara’s president and CEO, Rahul Ballal, said the designation reinforces “the unmet need for more effective treatment options for patients with sickle cell disease, a rare blood disorder characterized by debilitating pain, progressive multi-organ damage and early death.”
“We are making positive strides to advance IMR-687 for the treatment of sickle cell disease, including the recent initiation and patient dosing of our Phase 2b clinical trial for this patient population,” he added. Data from the Phase 2a portion are expected in the fourth quarter of 2020.
IMR-687 previously received FDA orphan drug, fast track and rare pediatric disease designations for the treatment of patients with sickle cell disease.